

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>SVF Investments (UK) Ltd</u> <hr/> (Last) (First) (Middle) <u>69 GROSVENOR STREET</u> <hr/> (Street) <u>LONDON X0 W1K 3JP</u> <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Axovant Gene Therapies Ltd. [ AXGT ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) <u>Former 10% Owner</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>07/10/2019</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person\*  
SVF Investments (UK) Ltd  


---

 (Last) (First) (Middle)  
69 GROSVENOR STREET  


---

 (Street)  
LONDON X0 W1K 3JP  


---

 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
SoftBank Vision Fund L.P.  


---

 (Last) (First) (Middle)  
AZTEC GROUP HOUSE  
11-15 SEATON PLACE  


---

 (Street)  
ST. HELIER X0 JE4 0QH  


---

 (City) (State) (Zip)

1. Name and Address of Reporting Person*		
<a href="#">SVF GP (Jersey) Ltd</a>		
(Last)	(First)	(Middle)
AZTEC GROUP HOUSE 11-15 SEATON PLACE		
(Street)		
ST. HELIER	X0	JE4 0QH
(City) (State) (Zip)		

1. Name and Address of Reporting Person*		
<a href="#">SVF Holdings (UK) LLP</a>		
(Last)	(First)	(Middle)
69 GROSVENOR STREET		
(Street)		
LONDON	X0	W1K 3JP
(City) (State) (Zip)		

**Explanation of Responses:**

**Remarks:**

This Form 4 relates to the Common Shares, \$0.00001 par value per share (the "Common Shares"), of Axovant Gene Therapies Ltd. (the "Issuer"). On July 10, 2019, the board of directors of Roivant Sciences Ltd. ("Roivant") adopted changes to Roivant's internal governance concerning the disposition of the Common Shares and other matters relating to oversight of Roivant's business and governance. As a result of these changes, the Reporting Persons and other major shareholders of Roivant no longer have the individual right to veto dispositive decisions of Roivant's board of directors regarding disposition of the Common Shares, and so have ceased to have beneficial ownership of the Common Shares directly owned by Roivant. Roivant's ownership of the Issuer's Common Shares remains unchanged and this filing is not being made as a result of the purchase or sale of Common Shares of the Issuer by any party, including the Reporting Persons.

<a href="#">/s/ Karen Ubell, Attorney-in-Fact</a>	<a href="#">07/12/2019</a>
<a href="#">/s/ Karen Ubell, Attorney-in-Fact</a>	<a href="#">07/12/2019</a>
<a href="#">/s/ Karen Ubell, Attorney-in-Fact</a>	<a href="#">07/12/2019</a>
<a href="#">/s/ Karen Ubell, Attorney-in-Fact</a>	<a href="#">07/12/2019</a>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**